Otsuka America Pharmaceutical - Publications - Faculty & Research - Harvard Business School

Filter Results: (338)

Filter Results: (338)

Show Results For

← Page 12 of 338 Results →

January 2014
Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie

The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details

Keywords: Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

May 2012 (Revised August 2014)
Case

McKesson

By: Regina E. Herzlinger and Natalie Kindred

McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into... View Details

Keywords: Health Care Industry; Health Care Policy; Organizational Transformations; Health Services; Health Care and Treatment; Business Model; Service Operations; Change Management; Corporate Strategy; Information Technology; Policy; Pharmaceutical Industry; Pharmaceutical Industry; United States

December 2005 (Revised October 2006)
Case

Pharmacy Service Improvement at CVS (A)

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details

Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States

April 1993 (Revised May 1994)
Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details

Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States

15 Jan 2018
Research & Ideas

A Better Business Model for Fighting Cancer

iPhoto With billions of dollars spent on the development of precision medicine and related cancer research over the last decade, a recent partnership seeks a new way to bring these treatments to patients more quickly: through a better business model. Founded in... View Details

Keywords: by Julia Hanna; Pharmaceutical; Pharmaceutical

October 2020
Teaching Plan

Merck: COVID-19 Vaccines

By: Willy C. Shih

COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details

Keywords: Vaccines; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Research and Development; Business Strategy; Pharmaceutical Industry; United States

September 2012 (Revised November 2014)
Case

Cialis Lifecycle Management: Lilly's BPH Dilemma

By: Elie Ofek and Natalie Kindred

How should Eli Lilly further develop and market a new indication of its highly successful erectile-dysfunction (ED) drug, Cialis, without confusing Cialis's hard-won brand equity with physicians and patients? With the final stages of clinical trials for the new... View Details

Keywords: Product Positioning; Attitudes; Brands and Branding; Pharmaceutical Industry; United States

July 2009 (Revised May 2010)
Case

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred

This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details

Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States

May 2002 (Revised October 2005)
Case

Marketing Antidepressants: Prozac and Paxil

By: Youngme E. Moon and Kerry Herman

Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details

Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States

March 1993
Supplement

Burroughs Wellcome and AZT (C)

By: Willis M. Emmons III

Describes key developments relating to Burroughs Wellcome, AZT and other AIDS drugs, and the AIDS issue in general from late 1989 through 1992. Includes excerpts from Wellcome PLC's financial statements and updated statistics on AIDS in the United States. View Details

Keywords: Health Pandemics; Multinational Firms and Management; Financial Statements; Pharmaceutical Industry; United States

January 2017
Supplement

Medtronic: Making the Big Leap Forward (B)

By: William W. George and Monica Baraldi

On December 1, 2014, Medtronic announced that it had completed a $17 billion bond sale to finance the Covidien acquisition, officially completed on January 26, 2015. Medtronic’s legal headquarters moved to Ireland, while its operational headquarters remained in... View Details

Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Integration; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States

August 2022
Article

Availability of New Medicines in the U.S. and Germany From 2004 to 2018

By: Katharina Blankart, Huseyin Naci and Amitabh Chandra

Importance: Germany's unique approach to coverage determination and pricing has ensured that effective medicines remain on the market, often at prices reduced through negotiation. However, less is known about trade-offs of this approach with regard to initial... View Details

Keywords: Market Entry and Exit; Price; Market Timing; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States; Germany

Register to Read

May 1992
Teaching Note

RU 486 (A) and (B), Teaching Note

By: Joseph L. Badaracco Jr.

Teaching Note for (9-391-050) and (9-391-051). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

October 1990 (Revised April 1991)
Case

RU 486 (A)

By: Joseph L. Badaracco Jr.

Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details

Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

01 Dec 2003
News

The Next Big Thing

life-sciences center of the world, by virtue of its unsurpassed “cluster” of world-renowned universities and teaching hospitals; medical-device, biotech, and pharmaceutical companies; financial firms; and skilled workers. “The leadership... View Details

Keywords: life sciences; Scientific Research and Development Services

October 2006
Teaching Note

Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)

By: Lynn S. Paine

Keywords: Pharmaceutical Industry; Argentina

01 Mar 2003
News

Inside the Revolution

care and life sciences issues, with the lion’s share focusing on the biotech and pharmaceutical industries. More than twenty HBS professors from different disciplines have contributed to this effort, which Pisano says is analogous to the... View Details

Keywords: Garry Emmons; Eileen McCluskey; Jonathan West; Life Sciences Project; LSP; Colleges, Universities, and Professional Schools; Educational Services

March 2018 (Revised January 2019)
Case

Gilead Mexico

By: Michael Chu and V. Kasturi Rangan

With a breakthrough cure for Hepatitis C listing in the U.S. at $1,000/pill, Gilead must now solve the issue of making it available to patients across the world, much as it did for its blockbuster HIV/AIDS antiretrovirals. For Erik Musalem, the new general manager of... View Details

Keywords: Health Care and Treatment; Price; Strategy; Management; Pharmaceutical Industry; Mexico

26 Jul 2016
Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Pharmaceutical; Pharmaceutical; Pharmaceutical

05 Jan 2011
Op-Ed

Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress

In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details

Keywords: by William Sahlman; Pharmaceutical; Pharmaceutical; Pharmaceutical

←
12
13
…
16
17
→